Related Experiment Video
Updated: Feb 5, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Metformin and blood cancers
Ademar Dantas Cunha Júnior1, Fernando Vieira Pericole1, Jose Barreto Campello Carvalheira1
1Departamento de Medicina Interna, Universidade Estadual de Campinas, Sao Paulo, SP, BR.
Abstract:
Type 2 diabetes mellitus and cancer are correlated with changes in insulin signaling, a pathway that is frequently upregulated in neoplastic tissue but impaired in tissues that are classically targeted by insulin in type 2 diabetes mellitus. Many antidiabetes treatments, particularly metformin, enhance insulin signaling, but this pathway can be inhibited by specific cancer treatments. The modulation of cancer growth by metformin and of insulin sensitivity by anticancer drugs is so common that this phenomenon is being studied in hundreds of clinical trials on cancer. Many meta-analyses have consistently shown a moderate but direct effect of body mass index on the incidence of multiple myeloma and lymphoma and the elevated risk of leukemia in adults. Moreover, new epidemiological and preclinical studies indicate metformin as a therapeutic agent in patients with leukemia, lymphomas, and multiple myeloma. In this article, we review current findings on the anticancer activities of metformin and the underlying mechanisms from preclinical and ongoing studies in hematologic malignancies.
Insights
Metformin, a type 2 diabetes drug, shows promise in treating blood cancers like leukemia and lymphoma. Research explores how it impacts insulin signaling in cancer and diabetes.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes mellitus and cancer share altered insulin signaling pathways.
- Metformin enhances insulin signaling, a pathway often dysregulated in cancer.
- Cancer therapies can inhibit insulin signaling, impacting diabetes treatments.
Purpose of the Study:
- To review metformin's anticancer activities in hematologic malignancies.
- To explore the mechanisms underlying metformin's effects on cancer growth and insulin sensitivity.
- To summarize findings from preclinical and ongoing clinical studies.
Main Methods:
- Review of preclinical studies on metformin's anticancer effects.
- Analysis of ongoing clinical trials investigating metformin in cancer.
- Examination of epidemiological data linking body mass index to hematologic cancer incidence.
Main Results:
- Metformin demonstrates therapeutic potential in leukemia, lymphomas, and multiple myeloma.
- Body mass index is moderately correlated with the incidence of multiple myeloma and lymphoma.
- Metformin's modulation of cancer growth and insulin sensitivity is under extensive clinical investigation.
Conclusions:
- Metformin exhibits significant anticancer properties in hematologic malignancies.
- Understanding the interplay between insulin signaling, diabetes, and cancer is crucial for therapeutic development.
- Further research is warranted to fully elucidate metformin's role in cancer therapy.
Related Concept Videos
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Composition of Blood
Formed elements constitute the remaining 45% of the blood volume. These...
Blood Flow
Blood Types
ABO blood group
ABO antigens are glycoproteins encoded by genes present on...
Blood Pressure

